Neurodegenerative Disorders
|
0.300 |
GeneticVariation
|
group |
BEFREE |
Mechanisms involving deregulated processing of proteins such as amyloid beta (Aβ) oligomerization; tau hyperphosphorylation, prion misfolding; α-synuclein accumulation/lewy body formation, chaperone deregulation, acetylcholine depletion, adenosine 2A (A2A) receptor hyperactivation, secretase deregulation, leucine-rich repeat kinase 2 (LRRK2) mutation and mitochondrial proteinopathies have deeper implications in neurodegenerative disorders.
|
31584139 |
2020 |
Neurodegenerative Disorders
|
0.300 |
Biomarker
|
group |
BEFREE |
Collectively, these results suggest that LRRK2 could be a potential molecular target for developing therapeutics to treat Mn-related neurodegenerative disorders.
|
30645642 |
2019 |
Neurodegenerative Disorders
|
0.300 |
Biomarker
|
group |
BEFREE |
Leucine rich repeat kinase 2 (LRRK2) is a key molecule in the pathogenesis of many neurodegenerative disorders.
|
29408508 |
2018 |
Neurodegenerative Disorders
|
0.300 |
GeneticVariation
|
group |
BEFREE |
Interestingly, Rab10 is a key substrate of leucine-rich repeat kinase 2 (LRRK2), a serine/threonine protein kinase genetically associated with the second most common neurodegenerative disease Parkinson's disease.
|
29562525 |
2018 |
Neurodegenerative Disorders
|
0.300 |
GeneticVariation
|
group |
BEFREE |
We believe that these findings provide important supplementary information about the regulatory mechanisms by which both variants influence PILRB and LRRK2 gene expression and neurodegenerative disease risk.
|
30619483 |
2018 |
Neurodegenerative Disorders
|
0.300 |
GeneticVariation
|
group |
BEFREE |
Several mutations in leucine rich repeat kinase 2 (LRRK2) gene have been associated with pathogenesis of Parkinson's disease (PD), a neurodegenerative disorder marked by resting tremors, and rigidity, leading to Postural instability.
|
29482628 |
2018 |
Neurodegenerative Disorders
|
0.300 |
Biomarker
|
group |
BEFREE |
The aim of this study was to identify new potentially active compounds for three protein targets, tropomyosin receptor kinase A (TrkA), <i>N</i>-methyl-d-aspartate (NMDA) receptor, and leucine-rich repeat kinase 2 (LRRK2), that are related to various neurodegenerative diseases such as Alzheimer's, Parkinson's, and neuropathic pain.
|
30044400 |
2018 |
Neurodegenerative Disorders
|
0.300 |
Biomarker
|
group |
BEFREE |
Although the physiological function of LRRK2 protein remains largely elusive, increasing evidence suggests that it plays a role in innate immunity, a process that also has been implicated in neurodegenerative diseases, including PD.
|
28202666 |
2017 |
Neurodegenerative Disorders
|
0.300 |
Biomarker
|
group |
BEFREE |
Four of these validated variants were nonsense mutations, six were observed in genes directly or indirectly related to neurodegenerative disorders (NDs), such as LPA, LRRK2, and FGF20.
|
27341347 |
2016 |
Neurodegenerative Disorders
|
0.300 |
GeneticVariation
|
group |
BEFREE |
Our results revealed clinical heterogeneity of the LRRK2 p.I2012T substitution, and demonstrated the use of targeted NGS for genetic diagnosis in multiplex families with PD or mixed neurodegenerative disorders.
|
27628070 |
2016 |
Neurodegenerative Disorders
|
0.300 |
Biomarker
|
group |
BEFREE |
Since LRRK2 is detected in tau-positive inclusions in brain tissue affected by various neurodegenerative disorders, including PD, LRRK2-stimulated phosphorylation of tau by GSK-3β may be involved in development of pathological features in the initial stage of PD.
|
24165324 |
2014 |
Neurodegenerative Disorders
|
0.300 |
Biomarker
|
group |
RGD |
Abrogation of α-synuclein-mediated dopaminergic neurodegeneration in LRRK2-deficient rats.
|
24927544 |
2014 |
Neurodegenerative Disorders
|
0.300 |
GeneticVariation
|
group |
BEFREE |
Parkinson disease is a progressive neurodegenerative disease for which leucine-rich repeat kinase 2 (LRRK2 carriers) p.G2019S confers substantial genotypic and population attributable risk.
|
24355527 |
2014 |
Neurodegenerative Disorders
|
0.300 |
GeneticVariation
|
group |
BEFREE |
Mutations in LRRK2 (leucine-rich repeat kinase 2) are the most frequent genetic lesions so far found in familial as well as sporadic forms of PD (Parkinson's disease), a neurodegenerative disease characterized by the dysfunction and degeneration of dopaminergic and other neuronal types.
|
22988863 |
2012 |
Neurodegenerative Disorders
|
0.300 |
GeneticVariation
|
group |
BEFREE |
In summary, the effective shRNA against LRRK2 R1441 alleles described herein suggests that RNAi-based therapy of inherited Parkinson's disease is a viable approach towards developing effective therapeutic interventions for this serious neurodegenerative disease.
|
21712955 |
2011 |
Neurodegenerative Disorders
|
0.300 |
GeneticVariation
|
group |
BEFREE |
The pleomorphic features exhibited by LRRK2 mutation carriers and the central role of Lrrk2 protein in the proper functioning of central nervous system suggest that mutations in this protein might be involved in multiple cellular processes leading to other neurodegenerative disorders than PD.
|
19822953 |
2009 |
Neurodegenerative Disorders
|
0.300 |
GeneticVariation
|
group |
BEFREE |
The predicted multifunctionality of LRRK2 product and the pleomorphic pathology associated with LRRK2 mutations place this gene as a potential candidate for other neurodegenerative disorders, mainly Alzheimer's disease (AD).
|
19072560 |
2008 |
Neurodegenerative Disorders
|
0.300 |
Biomarker
|
group |
BEFREE |
The clinical presentation of LRRK2-associated neurodegenerative disease may be more heterogeneous than previously assumed.
|
17914064 |
2008 |
Neurodegenerative Disorders
|
0.300 |
GeneticVariation
|
group |
LHGDN |
LRRK2 mutations were not encountered in other neurodegenerative disorders associated with synuclein and tau deposition.
|
18353371 |
2008 |
Neurodegenerative Disorders
|
0.300 |
Biomarker
|
group |
BEFREE |
These findings are significant in that they link LRRK2 with microtubules, a structural component of the cell that is critically involved in the pathogenesis of several neurodegenerative diseases, including PD.
|
18214993 |
2008 |
Neurodegenerative Disorders
|
0.300 |
Biomarker
|
group |
LHGDN |
The clinical presentation of LRRK2-associated neurodegenerative disease may be more heterogeneous than previously assumed.
|
17914064 |
2008 |
Neurodegenerative Disorders
|
0.300 |
GeneticVariation
|
group |
BEFREE |
LRRK2 mutations were not encountered in other neurodegenerative disorders associated with synuclein and tau deposition.
|
18353371 |
2008 |
Neurodegenerative Disorders
|
0.300 |
Biomarker
|
group |
BEFREE |
These findings may be coincidental; however, there is a small nucleus of LRRK2-positive patients displaying atypical features suggesting a role for this protein in other neurodegenerative disorders.
|
17151837 |
2007 |
Neurodegenerative Disorders
|
0.300 |
GeneticVariation
|
group |
BEFREE |
Pathogenic Lrrk2 Y1699C substitution observed in a large German-Canadian kindred presents a neurodegenerative disorder that is reminiscent of amyotrophic lateral sclerosis and Parkinsonism-Dementia Complex.
|
16865326 |
2007 |
Neurodegenerative Disorders
|
0.300 |
Biomarker
|
group |
BEFREE |
The possibility that Lrrk2 is linked with various neurodegenerative disorders through the ubiquitin proteosome pathway is discussed.
|
17639429 |
2007 |